Sara Bares, ACTIV 2021: Long-acting Injectable Antiretroviral Therapy for the Treatment of HIV
It was a pleasure to speak with Sara Bares (University of Nebraska, Omaha, NE, USA) to discuss long-acting injectable antiretroviral therapies for the treatment of HIV.
The abstract entitled: ‘Long Acting ART for Treatment of HIV’ was presented at the ACTHIV Virtual Conference 2021, May 20-22, 2021.
- What are the potential advantages and disadvantages of long-acting injectable (LAI) antiretroviral therapy (ART) for the treatment of HIV, compared to current treatment regimens? (0:15)
- Could you give us a brief overview of the FLAIR & ATLAS study objectives, and their findings? (2:51)
- Which patients are most likely to benefit from this regimen and in whom is it contraindicated? (4:49)
- What are the potential considerations/ challenges providers and patients may need to bear in mind before deciding to implement this regimen? (5:26)
Disclosures: Sara Bares has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the ACTHIV Virtual Conference 2021.
Share this Video
Related Videos In HIV
Sunil Solomon, CROI 2023: Unknowns and hurdles surrounding long-acting injectable PrEP for the prevention of HIV
touchINFECTIOUSDISEASES were delighted to speak with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the hurdles surrounding the use of long-acting injectable pre-exposure prophylaxis (PrEP) for the prevention of HIV in at-risk populations. Dr Solomon discussed the main barriers to conducting HIV research in at-risk populations, such as people […]
Sunil Solomon, CROI 2023: Current knowledge surrounding long-acting injectable PrEP for the prevention of HIV
It was a pleasure to talk with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the evidence from clinical trials for the use of long-acting injectables in the prevention of HIV and how long-acting injectable cabotegravir compares to oral pre-exposure prophylaxis (PrEP). Dr Solomon also discussed who is most […]
Nyaradzo Mgodi, CROI 2023: Long-acting injectable PrEP and cabotegravir roll-out for prevention of HIV- Factors affecting clinical practice and policy making
Long-acting injectable pre-exposure prophylaxis (PrEP) with cabotegravir has recently been approved as a new HIV prevention method. The preventative treatment involves receiving an injection of cabotegravir every two months to prevent HIV infection, rather than taking daily oral medication. The roll-out of this new prevention method is affected by several factors in both clinical practice […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!